← Back to home

FDA Rejects Capricor's Duchenne Cell Therapy Over Trial Data Flaws

Fact checked by NewsPlainVerified by NewsPlain: confirmed by at least two named sources

Brief

The Food and Drug Administration sent a formal rejection letter on Nov. 20 declining to approve deramiocel, Capricor Therapeutics' cell therapy…

Keep reading with NewsPlain Premium

Get the full brief, the full story, what's confirmed, what's still unclear, why it matters, and every source.

5 confirmed facts, 1 open question and 2 sources behind this story.

About this story

We haven’t published a correction to this story.

How NewsPlain works
← Back to home